Comparison of INNO-LiPA Genotyping Extra and Hybrid Capture 2 assays for detection of carcinogenic human papillomavirus genotypes

Journal of Clinical Virology

Volumn 55, Issue 3, 2012, Pages 256-261

  Barzon, Luisa ^a,b   Militello, Valentina ^a,b   Pagni, Silvana ^a,b   Palù, Giorgio ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Cervical cancer screening; HPV genotyping; Human papillomavirus; Hybrid capture 2; Line probe assay

Indexed keywords

ARTICLE; CANCER SCREENING; CONTROLLED STUDY; FEMALE; GENOTYPING TECHNIQUE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYBRID CAPTURE 2 ASSAY; INNO LIPA HUMAN PAPILLOMA VIRUS GENOTYPING EXTRAS ASSAY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; WART VIRUS;

ADULT; CERVIX UTERI; CROSS-SECTIONAL STUDIES; CYTOLOGICAL TECHNIQUES; FEMALE; GENOTYPE; HISTOCYTOCHEMISTRY; HUMANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; VIROLOGY;

EID: 84866393948     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2012.07.013     Document Type: Article

References (26)

1. Bouvard V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., et al. A review of human carcinogens. Part B. Biological agents. Lancet Oncol 2009, 10:321-322.
2. Barzon L., Giorgi C., Buonaguro F.M., Palù G. Italian Society for Virology Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention. Infect Agent Cancer 2008, 3:14.
3. Schiffman M., Wentzensen N., Wacholder S., Kinney W., Gage J.C., Castle P.E. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011, 103:368-383.
4. Khan M.J., Castle P.E., Lorincz A.T., Wacholder S., Sherman M., Scott D.R., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005, 97:1072-1079.
5. Ronco G., Giorgi-Rossi P., Carozzi F., Confortini M., Dalla Palma P., Del Mistro A., et al. New Technologies for Cervical Cancer screening (NTCC) Working Group Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010, 11:249-257.
6. Rijkaart D.C., Berkhof J., Rozendaal L., van Kemenade F.J., Bulkmans N.W., Heideman D.A., et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012, 13:78-88.
7. Castle P.E., Stoler M.H., Wright T.C., Sharma A., Wright T.L., Behrens C.M. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 2011, 12:880-890.
8. Rijkaart D.C., Berkhof J., van Kemenade F.J., Coupe V.M., Hesselink A.T., Rozendaal L., et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 2012, 130:602-610.
9. Meijer C.J., Berkhof J., Castle P.E., Hesselink A.T., Franco E.L., Ronco G., et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009, 124:516-520.
10. Meijer C.J., Berkhof H., Heideman D.A., Hesselink A.T., Snijders P.J. Validation of high-risk HPV tests for primary cervical screening. J Clin Virol 2009, 46(Suppl. 3):S1-S4.
11. Eklund C., Zhou T., Dillner J. WHO Human Papillomavirus Laboratory Network Global proficiency study of human papillomavirus genotyping. J Clin Microbiol 2010, 48:4147-4155.
12. Gravitt P.E., Schiffman M., Solomon D., Wheeler C.M., Castle P.E. A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study. Cancer Epidemiol Biomarkers Prev 2008, 17:1248-1254.
13. Castle P.E., Schiffman M., Burk R.D., Wacholder S., Hildesheim A., Herrero R., et al. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol Biomarkers Prev 2002, 11:1394-1399.
14. Poljak M., Marin I.J., Seme K., Vince A. Hybrid Capture II HPV test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. J Clin Virol 2002, 25(Suppl. 3):S89-S97.
15. Castle P.E., Solomon D., Wheeler C.M., Gravitt P.E., Wacholder S., Schiffman M. Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol 2008, 46:2595-2604.
16. Safaeian M., Herrero R., Hildesheim A., Quint W., Freer E., Van Doorn L.J., et al. Costa Rican Vaccine Trial Group. Comparison of the SPF10-LiPA system to the Hybrid Capture 2 Assay for detection of carcinogenic human papillomavirus genotypes among 5 683 young women in Guanacaste, Costa Rica. J Clin Microbiol 2007, 45:1447-1454.
17. Hesselink A.T., van Ham M.A., Heideman D.A., Groothuismink Z.M., Rozendaal L., Berkhof J., et al. Comparison of GP5+/6+-PCR and SPF10-line blot assays for detection of high-risk human papillomavirus in samples from women with normal cytology results who develop grade 3 cervical intraepithelial neoplasia. J Clin Microbiol 2008, 46:3215-3221.
18. Eklund C., Zhou T., Dillner J. Global proficiency study of human papillomavirus genotyping. J Clin Microbiol 2010, 48:4147-4155.
19. Steinau M., Onyekwuluje J.M., Scarbrough M.Z., Unger E.R., Dillner J., Zhou T. Performance of commercial reverse line blot assay for human papillomavirus genotyping. J Clin Microbiol 2012, 50:1539-1544.
20. Militello V., Trevisan M., Squarzon L., Biasolo M.A., Rugge M., Militello C., et al. Investigation on the presence of polyomavirus, herpesvirus, and papillomavirus sequences in colorectal neoplasms and their association with cancer. Int J Cancer 2009, 124:2501-2503.
21. Schmitz M., Scheungraber C., Herrmann J., Teller K., Gajda M., Runnebaum I.B., et al. Quantitative multiplex PCR assay for the detection of the seven clinically most relevant high-risk HPV types. J Clin Virol 2009, 44:302-307.
22. Depuydt C.E., Benoy I.H., Bailleul E.J., Vandepitte J., Vereecken A.J., Bogers J.J. Improved endocervical sampling and HPV viral load detection by Cervex-Brush Combi. Cytopathology 2006, 17:374-381.
23. Else E.A., Swoyer R., Zhang Y., Taddeo F.J., Bryan J.T., Lawson J., et al. Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with INNO-LiPA HPV genotyping extra assay. J Clin Microbiol 2011, 49:1907-1912.
24. Perrons C., Jelley R., Kleter B., Quint W., Brink N. Detection of persistent high risk human papillomavirus infections with hybrid capture II and SPF10/LiPA. J Clin Virol 2005, 32:278-285.
25. Barzon L., Militello V., Pagni S., Franchin E., Dal Bello F., Mengoli C., et al. Distribution of human papillomavirus types in the anogenital tract of females and males. J Med Virol 2010, 82:1424-1430.
26. Barzon L., Militello V., Lavezzo E., Franchin E., Peta E., Squarzon L., et al. Human papillomavirus genotyping by 454 next generation sequencing technology. J Clin Virol 2011, 52:93-97.